Inger Johansson

Publications
Public outreach and news

Articles

Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2022;112(5):1000-1003
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination
Pridgeon CS; Johansson I; Ingelman-Sundberg M
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2022;111(5):1165-1174
The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients
Lenk HC; Kloditz K; Johansson I; Smith RL; Jukic M; Molden E; Ingelman-Sundberg M
Article: SCIENCE TRANSLATIONAL MEDICINE. 2021;13(603):eabf3637
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
van der Lee M; Allard WG; Vossen RHAM; Baak-Pablo RF; Menafra R; Deiman BALM; Deenen MJ; Neven P; Johansson I; Gastaldello S; Ingelman-Sundberg M; Guchelaar H-J; Swen JJ; Anvar SY
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2020;108(4):844-855
Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes
Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling A; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
Article: CELLS. 2020;9(4):E964-964
Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Hurrell T; Kastrinou-Lampou V; Fardellas A; Hendriks DFG; Nordling A; Johansson I; Baze A; Parmentier C; Richert L; Ingelman-Sundberg M
Article: SCIENTIFIC REPORTS. 2018;8(1):14297
Human hepatic 3D spheroids as a model for steatosis and insulin resistance
Kozyra M; Johansson I; Nordling A; Ullah S; Lauschke VM; Ingelman-Sundberg M
Article: HEPATOLOGY. 2016;64(5):1743-1756
Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation
Lauschke VM; Vorrink SU; Moro SML; Rezayee F; Nordling A; Hendriks DFG; Bell CC; Sison-Young R; Park BK; Goldring CE; Ellis E; Johansson I; Mkrtchian S; Andersson TB; Ingelman-Sundberg M
Article: FEBS LETTERS. 2016;590(3):330-339
Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1
Guo J; Thiess S; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Article: PLOS ONE. 2016;11(9):e0162379
Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas
Nole P; Duijndam B; Stenman A; Juhlin CC; Kozyra M; Larsson C; Ingelman-Sundberg M; Johansson I
Article: STEM CELLS INTERNATIONAL. 2016;2016:2475631
High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
Pradip A; Steel D; Jacobsson S; Holmgren G; Ingelman-Sundberg M; Sartipy P; Bjorquist P; Johansson I; Edsbagge J
Article: CLINICAL CANCER RESEARCH. 2015;21(2):322-328
Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
Apellaniz-Ruiz M; Lee M-Y; Sanchez-Barroso L; Gutierrez-Gutierrez G; Calvo I; Garcia-Estevez L; Sereno M; Garcia-Donas J; Castelo B; Guerra E; Leandro-Garcia LJ; Cascon A; Johansson I; Robledo M; Ingelman-Sundberg M; Rodriguez-Antona C
Article: PLOS ONE. 2015;10(4):e0122820
Developmental Regulation and Induction of Cytochrome P450 2W1, an Enzyme Expressed in Colon Tumors
Choong E; Guo J; Persson A; Virding S; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Article: PHARMACOGENOMICS. 2015;16(9):929-937
Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity
Lee M-Y; Apellaniz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brosen K; Green H; Rodriguez-Antona C; Ingelman-Sundberg M
Article: PHARMACOGENOMICS JOURNAL. 2014;14(4):343-349
High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase
Lee M-Y; Borgiani P; Johansson I; Oteri F; Mkrtchian S; Falconi M; Ingelman-Sundberg M
Article: ACTA ONCOLOGICA. 2014;53(7):885-891
The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases
Stenstedt K; Hallstrom M; Ledel F; Ragnhammar P; Ingelman-Sundberg M; Johansson I; Edler D
Article: PHARMACOGENOMICS. 2013;14(13):1615-1622
CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer
Stenstedt K; Travica S; Guo J; Barragan I; Pors K; Patterson L; Edler D; Mkrtchian S; Johansson I; Ingelman-Sundberg M
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2013;56(15):6273-6277
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity
Sheldrake HM; Travica S; Johansson I; Loadman PM; Sutherland M; Elsalem L; Illingworth N; Cresswell AJ; Reuillon T; Shnyder SD; Mkrtchian S; Searcey M; Ingelman-Sundberg M; Patterson LH; Porst K
Article: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2013;113(2):126-131
Sex Difference in Formation of Propofol Metabolites: A Replication Study
Choong E; Loryan I; Lindqvist M; Nordling A; el Bouazzaoui S; van Schaik RH; Johansson I; Jakobsson J; Ingelman-Sundberg M
Article: CLINICAL CANCER RESEARCH. 2013;19(11):2952-2961
Colon Cancer-Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins
Travica S; Pors K; Loadman PM; Shnyder SD; Johansson I; Alandas MN; Sheldrake HM; Mkrtchian S; Patterson LH; Ingelman-Sundberg M
Article: ANTICANCER RESEARCH. 2012;32(9):3869-3874
The Expression of CYP2W1: A Prognostic Marker in Colon Cancer
Stenstedt K; Hallstrom M; Johansson I; Ingelman-Sundberg M; Ragnhammar P; Edler D
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2012;68(4):397-406
Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia
Loryan I; Lindqvist M; Johansson I; Hiratsuka M; van der Heiden I; van Schaik RHN; Jakobsson J; Ingelman-Sundberg M
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2012;287(9):6307-6317
Amidoxime Reductase System Containing Cytochrome b₅ Type B (CYB5B) and MOSC2 Is of Importance for Lipid Synthesis in Adipocyte Mitochondria
Neve EPA; Nordling A; Andersson TB; Hellman U; Diczfalusy U; Johansson I; Ingelman-Sundberg M
Article: ATLA ALTERNATIVES TO LABORATORY ANIMALS. 2011;39(2):147-171
Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines - A Report on the Vitrocellomics EU-project
Mandenius C-F; Andersson TB; Alves PM; Batzl-Hartmann C; Bjorquist P; Carrondo MJT; Chesne C; Coecke S; Edsbagge J; Fredriksson JM; Gerlach JC; Heinzle E; Ingelman-Sundberg M; Johansson I; Kuppers-Munther B; Mueller-Vieira U; Noor F; Zeilinger K
Article: TOXICOLOGICAL SCIENCES. 2011;120(1):1-13
Genetic Polymorphism and Toxicology-With Emphasis on Cytochrome P450
Johansson I; Ingelman-Sundberg M
Article: MOLECULAR PHARMACOLOGY. 2010;78(6):1004-1011
Colorectal Cancer-Specific Cytochrome P450 2W1: Intracellular Localization, Glycosylation, and Catalytic Activity
Gomez A; Nekvindova J; Travica S; Lee M-Y; Johansson I; Edler D; Mkrtchian S; Ingelman-Sundberg M
Article: JOURNAL OF BIOTECHNOLOGY. 2010;145(3):284-294
Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage
Brolen G; Sivertsson L; Bjorquist P; Eriksson G; Ek M; Semb H; Johansson I; Andersson TB; Ingelman-Sundberg M; Heins N
Article: JOURNAL OF HEPATOLOGY. 2009;50(3):572-583
The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model
Butura A; Nilsson K; Morgan K; Morgan TR; French SW; Johansson I; Schuppe-Koistinen I; Ingelman-Sundberg M
Article: CYTOGENETIC AND GENOME RESEARCH. 2008;123(1-4):195-204
CNVs of human genes and their implication in pharmacogenetics
Johansson I; Ingelman-Sundberg M
Article: BIOCHEMICAL PHARMACOLOGY. 2007;74(3):496-503
Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells
Ek M; Soderdahl T; Kuppers-Munther B; Edsbagge J; Andersson TB; Bjorquist P; Cotgreave I; Jernstrom B; Ingelman-Sundberg M; Johansson I
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;341(2):451-458
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
Karlgren M; Gomez A; Stark K; Svärd J; Rodriguez-Antona C; Oliw E; Bernal ML; Cajal SRY; Johansson I; Ingelman-Sundberg M
Article: ATHEROSCLEROSIS. 2005;182(1):37-45
Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration
Abrahamsson A; Krapivner S; Gustafsson U; Muhrbeck O; Eggertsen G; Johansson I; Persson I; Angelin B; Ingelman-Sundberg M; Björkhem I; Einarsson C; van't Hooft FM
Article: DRUG METABOLISM AND DISPOSITION. 2005;33(4):570-578
Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime
Andersson S; Hofmann Y; Nordling Å; Li XQ; Nivelius S; Andersson TB; Ingelman-Sundberg M; Johansson I
Article: BIOCHEMICAL PHARMACOLOGY. 2004;67(7):1249-1258
Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling
Butura A; Johansson I; Nilsson K; Wärngård L; Ingelman-Sundberg M; Schuppe-Koistinen I
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2004;315(3):679-685
Characterization and tissue distribution of a novel human cytochrome P450 - CYP2U1
Karlgren M; Backlund M; Johansson I; Oscarson M; Ingelman-Sundberg M
Article: DRUG METABOLISM AND DISPOSITION. 2003;31(6):755-761
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2002;58(1):19-27
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis
Thapar MM; Ashton M; Lindegårdh N; Bergqvist Y; Nivelius S; Johansson I; Björkman A
Article: PHARMACOGENETICS AND GENOMICS. 2001;11(5):417-427
Characterization of the CYP2D6*29 allele commonly present in a blade Tanzanian population causing reduced catalytic activity
Wennerholm A; Johansson I; Hidestrand M; Bertilsson L; Gustafsson LL; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2000;56(9-10):679-683
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Article: PSYCHOPHARMACOLOGY. 1999;147(3):300-305
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(6):707-714
Decreased capacity for debrisoquine metabolism among black Tanzanians:: analyses of the CYP2D6 genotype and phenotype
Wennerholm A; Johansson I; Massele AY; Jande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(5):657-660
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl ML; Ingelman-Sundberg M; Bertilsson L
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;81(3):325-329
Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients
Persson I; Johansson I; Lou YC; Yue QY; Duan LS; Bertilsson L; Ingelman-Sundberg M
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;254(3):628-631
Validation of methods for CYP2C9 genotyping:: Frequencies of mutant alleles in a Swedish population
Yasar Ü; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjoqvist F
Article: GENE. 1999;226(2):327-338
Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
Lundqvist E; Johansson I; Ingelman-Sundberg M
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 1998;64(4):391-401
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Article: PHARMACOGENETICS AND GENOMICS. 1998;8(2):119-123
Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction
Bathum L; Johansson I; Ingelman-Sundberg M; Horder M; Brosen K
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1997;272(50):31755-31763
Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells
Backlund M; Johansson I; Mkrtchian S; IngelmanSundberg M
Article: MOLECULAR PHARMACOLOGY. 1997;52(6):1034-1040
A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function
Oscarson M; Hidestrand M; Johansson I; Ingelman-Sundberg M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1997;44(5):439-446
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
Article: MOLECULAR PHARMACOLOGY. 1997;51(3):370-376
Genetic polymorphism of human CYP2E1: Characterization of two variant alleles
Hu Y; Oscarson M; Johansson I; Yue QY; Dahl ML; Tabone M; Arinco S; Albano E; IngelmanSundberg M
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1997;231(1):227-230
In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility
Persson I; Johansson I; IngelmanSundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1997;280(1):506-511
Selective centrilobular expression of the aryl hydrocarbon receptor in rat liver
Lindros KO; Oinonen T; Johansson I; IngelmanSundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1996;51(2):117-122
Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population - Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; IngelmanSundberg M
Article: JOURNAL OF HEPATOLOGY. 1996;25(4):538-546
Hepatotoxicity induced by iron overload and alcohol - Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation
Stal P; Johansson I; IngelmanSundberg M; Hagen K; Hultcrantz R
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(5):441-447
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population
Roh HK; Dahl ML; Johansson I; IngelmanSundberg M; Cha YN; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(4):351-355
PCR-based genotyping for duplicated and deleted CYP2D6 genes
Johansson I; Lundqvist E; Dahl ML; IngelmanSundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1996;278(1):441-446
Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; IngelmanSundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1995;274(1):516-520
ULTRARAPID HYDROXYLATION OF DEBRISOQUINE IN A SWEDISH POPULATION - ANALYSIS OF THE MOLECULAR-GENETIC BASIS
DAHL ML; JOHANSSON I; BERTILSSON L; INGELMANSUNDBERG M; SJOQVIST F
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1995;39(6):611-620
BIOTRANSFORMATION AND PHARMACOKINETICS OF ETHYLMORPHINE AFTER A SINGLE ORAL DOSE
AASMUNDSTAD TA; XU BQ; JOHANSSON I; RIPEL A; BJORNEBOE A; CHRISTOPHERSEN AS; BODD E; MORLAND J
Article: PHARMACOGENETICS AND GENOMICS. 1995;5(3):159-164
GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS
DAHL ML; YUE QY; ROH HK; JOHANSSON I; SAWE J; SJOQVIST F; BERTILSSON L
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 1995;57(6):656-661
PHENOTYPING AND GENOTYPING OF S-MEPHENYTOIN HYDROXYLASE (CYTOCHROME-P450 2C19) IN A SHONA POPULATION OF ZIMBABWE
MASIMIREMBWA C; BERTILSSON L; JOHANSSON I; HASLER JA; INGELMANSUNDBERG M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1995;48(1):35-38
INHIBITORY EFFECTS OF ANTIPARASITIC DRUGS ON CYTOCHROME-P450 2D6
MASIMIREMBWA CM; HASLER JA; JOHANSSON I
Show more

All other publications

Letter: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2022;112(6):1155
Response to Rowland et al. and Achour et al.
Pridgeon CS; Johansson I; Ingelman-Sundberg M
Review: DRUG METABOLISM REVIEWS. 2016;48(3):369-378
The CYP2W1 enzyme: regulation, properties and activation of prodrugs
Guo J; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Other: DRUG NEWS AND PERSPECTIVES. 2008;21(9):518-528
Current research in drug metabolism, drug transport and drug development.
Johansson I; Ingelman-Sundberg M
Other: DRUG NEWS AND PERSPECTIVES. 2004;17(9):594-605
New approaches and applications in chemical biology.
Gomez A; Ingelman-Sundberg M; Johansson I; Karlgren M; Rodriguez-Antona C; Sim SC
Published conference paper: DRUG METABOLISM AND DISPOSITION. 2004;32(5):484-489
The impact of CYP2C9 genetics and oral contraceptives on cytochrome P4502C9 phenotype
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Published conference paper: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2001;281(5):1349-1355
Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43
Westlind A; Malmebo S; Johansson I; Otter C; Andersson TB; Ingelman-Sundberg M; Oscarson M

Articles

All other publications

News from KI

Events from KI